{
    "clinical_study": {
        "@rank": "65259", 
        "arm_group": {
            "arm_group_label": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
            "arm_group_type": "Experimental", 
            "description": "0.5 ml/ vial"
        }, 
        "brief_summary": {
            "textblock": "The clinical trial was designed to evaluate the safety and immunogenicity against Group\n      ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of\n      age and older."
        }, 
        "brief_title": "Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002", 
        "completion_date": {
            "#text": "June 2006", 
            "@type": "Actual"
        }, 
        "condition": "Meningitis", 
        "condition_browse": {
            "mesh_term": "Meningitis"
        }, 
        "detailed_description": {
            "textblock": "Complying with requirements of the approval letter of clinical trial issued by SFDA\n      (Approval Letter No.: 2006L01017), Hualan conducted phase II clinical trial of Group ACYW135\n      Meningococcal Polysaccharide Vaccine to evaluate the safety and immunogenicity of the\n      experimental vaccine.\n\n      The safety end points were the presence of any systemic, local and adverse reaction.\n      Evaluation indicators of immunogenicity were bacteriocin levels of groups A, C, Y and W135\n      respectively in the serum after the whole vaccination."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy permanent residence 2 years of age and older, the subjects (or their\n             guardians) are able to understand and sign the informed consent;\n\n          -  Healthy male or female by oral history, physical examination and clinical judgment\n             and who complies with vaccination of this product;\n\n          -  Be able to comply with the requirements of clinical trial protocol and immunogenicity\n             examination;\n\n          -  Have no history of vaccination within the past 3 months and vaccination with other\n             products within the last 2 weeks;\n\n          -  Axillary temperature \u226437.0\u2103.\n\n        Exclusion Criteria:\n\n          -  Any acute disease, such as: tumor, autoimmunity disease, progressive atherosclerotic\n             disease or diabetes with complication, chronic obstructive pulmonary disease need\n             oxygen uptake, acute or progressive hepatopathy or nephropathy, congestive\n             heart-failure, etc.;\n\n          -  Allergic to vaccines or drugs (history of allergy to any vaccine in the past);\n\n          -  History of neurologic symptom or signs;\n\n          -  Known or suspected (or high risk) impaired or abnormal immune function, e.g.: receive\n             immunosuppressant or immunopotentiator therapy, take immunoglobulin or blood product\n             or plasma extract (except the gastrointestinal tract) within the past 3 months, HIV\n             infection or related disease, etc.;\n\n          -  History of meningitis infection or vaccination of meningococcal vaccine within the\n             past 3 months;\n\n          -  History of receiving other vaccines or immunoglobulin injection or any research\n             drugs;\n\n          -  Any acute disease needing application of antibiotics or anti-virus treatment in the\n             whole body within the past 1 week;\n\n          -  History of fever within the past 3 days (axillary temperature \u226538.0\u2103);\n\n          -  Participating in another clinical trial;\n\n          -  History of allergy, eclampsia, epilepsy, encephalopathy and mental disease or family\n             disease;\n\n          -  Thrombopenia or other coagulopathy that may cause contraindication to intramuscular\n             injection;\n\n          -  Acute chronic disease (such as Down syndrome, diabetes, sickle cell anemia or\n             neurologic disease, Guillain-Barre Syndrome);\n\n          -  Known or suspected diseases, including: respiratory system disease, acute infection\n             or active stage of chronic disease, SBAV infection of children or mothers,\n             cardiovascular disease, acute hypertension, cancer treatment, skin disease, etc.;\n\n          -  Pregnancy\n\n          -  Any condition that, in the judgment of investigator, may affect trial assessment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661738", 
            "org_study_id": "Hualanbio-Meningococcal CT 002", 
            "secondary_id": "Hualanbio-phase II CT"
        }, 
        "intervention": {
            "arm_group_label": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
            "description": "360 subjects were divided into three groups (120 subjects in each group), children (2~6 years of age),  early youth (7~15 years of age) and adult (16~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime", 
            "intervention_name": "Group ACYW135 Meningococcal Polysaccharide Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Hualan Bio"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Group ACYW135 Meninigococcal Polysaccharide Vaccine", 
        "lastchanged_date": "August 6, 2012", 
        "number_of_arms": "1", 
        "official_title": "Phase II Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine", 
        "overall_official": {
            "affiliation": "Immunization Program Institute of Jiangsu Provincial Center for Disease Control and Prevention", 
            "last_name": "Fubao Ma, Bachelor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Systemic and local adverse reactions after the vaccination; adverse events", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Day 28 after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661738"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "4-fold (seroconversion) and 8-fold increase of bactericidin; GMT and bactericidin increase after immunization", 
            "measure": "Immunogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "The 4th week after immunization"
        }, 
        "source": "Hualan Biological Engineering, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hualan Biological Engineering, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2006", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}